What You Should Know:
– House Rx, a health tech company focused on making specialty medications more accessible and affordable for patients, today announced it has raised $55 million in Series B equity and debt to expand its in-clinic specialty pharmacy model.
– The financing was led by New Enterprise Associates (NEA) and Town Hall Ventures and included participation from LRVHealth, First Round Capital, Bessemer Venture Partners, and Silicon Valley Bank. This new investment brings the company’s total capital raised to date to $100 million.
House Rx Redefines Specialty Pharmacy with Medically Integrated, AI-Enabled Care Model
House Rx is transforming specialty pharmacy by empowering clinics to dispense medications directly to their patients through a medically integrated, technology-driven model. Combining pharmacist expertise with modern software, House Rx fosters real-time collaboration between physicians and pharmacists to enhance patient outcomes, lower costs, and deliver a superior care experience. Founded in 2021, the company has grown to nearly 250 employees and was recently named one of Time Magazine’s World’s Top HealthTech Companies of 2025.
As regulators and states intensify scrutiny of Pharmacy Benefit Manager (PBM)-owned, closed-network specialty pharmacies, House Rx is advancing a scalable alternative: a nationwide network of locally owned, clinic-embedded specialty dispensaries. This decentralized model places patients and providers at the center of care, replacing fragmented fulfillment systems with a high-touch, integrated experience. By embedding pharmacy operations within specialty clinics, House Rx streamlines coordination, reduces administrative friction, and improves outcomes for patients managing complex conditions.
“There’s finally momentum behind building a specialty pharmacy ecosystem that makes it easier and more affordable for patients to access the medications they need,” said Ogi Kavazovic, CEO and Founder of House Rx. “We’re seeing enthusiasm from providers, manufacturers, payers, investors, and employees who recognize the chance to challenge the status quo—improving care for patients while tackling unsustainable costs. With new funding, we’re ready to scale rapidly to meet this growing demand.”
To date, House Rx has partnered with over 1,000 providers across 80 clinic sites nationwide, supporting them in launching and managing in-house specialty pharmacies. The company currently processes around $1.5 billion in specialty prescriptions annually, a figure projected to reach $3 billion by 2026.
At the core of this growth is House Rx’s proprietary pharmacy management platform, purpose-built for medically integrated dispensaries and equipped with AI-powered workflows that drive efficiency and scale. In April, the company introduced Smart PA, an artificial intelligence feature that automates 80% of pharmacy prior authorizations, significantly reducing administrative burdens. Additional AI capabilities are now in development, each designed to be natively embedded within the House Rx system—further strengthening its position as the operational backbone for a new era of local, connected specialty pharmacy care.
